Article

Stem Cell Ruling Blocks "Life-saving" Research, White House Says

Author(s):

A new ruling has set back the Obama administration's efforts to expand stem-cell research yesterday after a judge issued a preliminary injuction which prevents the federal government from funding any medical research related to embryonic stem cells.

A new ruling has set back the Obama administration’s efforts to expand stem-cell research yesterday after a judge issued a preliminary injuction which prevents the federal government from funding any medical research related to embryonic stem cells. US Chief District Court Judge Royce Lamberth made the ruling based on the premise that the proposal “violated a 1996 law intended to prevent the destruction of human embryos.

The decision has led to a variety of reactions from outspoken leaders on both sides of the debate.

The New York Times writes that Ron Stoddart, executive director of Nightlight Christian Adoptions, was pleased with the judge’s ruling, and said that he did not to see stem-cell research that destroyed embryos. “Embryos are preborn human life that should be protected and not destroyed. If there was a way of extracting the stem cells without destroying them, I would not be opposed to it,” said Stoddart.

According to the Washington Post, many scientists have condemned the restrictions, saying that the ruling hinders important research that could lead to cures for conditions such as Alzheimer’s disease, diabetes, and paralysis.

The Wall Street Journal reports that it is still unclear as to whether or not the judge’s decision would affect currently funded stem-cell research projects.

What’s your take on the judge’s ruling? Should embryonic stem-cell research be federally funded?

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.